BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010;30:75-86. [PMID: 20175035 DOI: 10.1055/s-0030-1247134] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Srivani G, Imran M, Merchant N, Mandala JP, Nagaraju GP. Role of succinate dehydrogenase in hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00014-3] [Reference Citation Analysis]
2 Liang XH, Feng ZP, Liu FQ, Yan R, Yin LY, Shen H, Lu HL. Identification of potential biomarkers for diagnosis of hepatocellular carcinoma. Exp Ther Med 2022;23:51. [PMID: 34917180 DOI: 10.3892/etm.2021.10973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ding Q, Jiang C, Zhou Y, Duan J, Lai J, Jiang M, Lin D. Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway. Biosci Biotechnol Biochem 2021;85:2241-9. [PMID: 34494081 DOI: 10.1093/bbb/zbab154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shiu TY, Lin HH, Shih YL, Feng AC, Huang HH, Huang TY, Hsieh CB, Chang WK, Hsieh TY. CRNDE-h transcript/miR-136-5p axis regulates interleukin enhancer binding factor 2 expression to promote hepatocellular carcinoma cell proliferation. Life Sci 2021;:119708. [PMID: 34153299 DOI: 10.1016/j.lfs.2021.119708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tu Y, Liu Z, Wang F, Liu P, Tao J, Li C, Han Z, Li Z, Ma Y, Gu Y. AT1R-Specific Ligand Angiotensin II as a Novel SPECT Agent for Hepatocellular Carcinoma Diagnosis. ACS Sens 2020;5:4072-80. [PMID: 33232127 DOI: 10.1021/acssensors.0c02180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Duan X, Liu J, Cui J, Ma B, Zhou Q, Yang X, Lu Z, Du Y, Su C. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Mol Med Rep 2019;20:3773-81. [PMID: 31485637 DOI: 10.3892/mmr.2019.10641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
7 Kovi RC, Bhusari S, Mav D, Shah RR, Ton TV, Hoenerhoff MJ, Sills RC, Pandiri AR. Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. Arch Toxicol 2019;93:2219-35. [PMID: 31278416 DOI: 10.1007/s00204-019-02505-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhang XL, Pan SH, Yan JJ, Xu G. The prognostic value of microRNA-183 in human cancers: A meta-analysis. Medicine (Baltimore) 2018;97:e11213. [PMID: 29952976 DOI: 10.1097/MD.0000000000011213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
9 Tseng PL, Wu WH, Hu TH, Chen CW, Cheng HC, Li CF, Tsai WH, Tsai HJ, Hsieh MC, Chuang JH, Chang WT. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci Rep 2018;8:3081. [PMID: 29449614 DOI: 10.1038/s41598-018-21361-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
10 Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget. 2016; Epub ahead of print. [PMID: 27276713 DOI: 10.18632/oncotarget.9801] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
11 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
12 Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone FA, Baldassarre M, Quarta S, Vandewynckel YP, Vandierendonck A, Van Vlierberghe H, Porretti L, Negrini M, Bolondi L, Gramantieri L, Fornari F. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis 2018;9:4. [PMID: 29305580 DOI: 10.1038/s41419-017-0076-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
13 Sulas P, Di Tommaso L, Novello C, Rizzo F, Rinaldi A, Weisz A, Columbano A, Roncalli M. A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development. Am J Pathol. 2018;188:785-794. [PMID: 29248455 DOI: 10.1016/j.ajpath.2017.10.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud Nelson M, Qu W, Feng B, Pi J. Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer 2017;117:1495-506. [PMID: 28910823 DOI: 10.1038/bjc.2017.317] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
15 Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y. GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. J Clin Invest 2017;127:3527-42. [PMID: 28758902 DOI: 10.1172/JCI93488] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
16 Li Q, Li S, Wu Y, Gao F. miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3. Oncol Lett 2017;14:2552-8. [PMID: 28789462 DOI: 10.3892/ol.2017.6429] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
17 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer. 2017;12:27. [PMID: 28529542 DOI: 10.1186/s13027-017-0138-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
18 Chen J, Rajasekaran M, Hui KM. Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma. Exp Biol Med (Maywood) 2017;242:1142-9. [PMID: 28429652 DOI: 10.1177/1535370217705865] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
19 Pascale RM, Joseph C, Latte G, Evert M, Feo F, Calvisi DF. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma? DNA Repair 2016;47:12-20. [DOI: 10.1016/j.dnarep.2016.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
20 Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair. Endocr Relat Cancer. 2016;23:R353-R369. [PMID: 27353037 DOI: 10.1530/erc-16-0152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
21 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 461] [Cited by in F6Publishing: 477] [Article Influence: 65.9] [Reference Citation Analysis]
22 Peng YY, He YH, Chen C, Xu T, Li L, Ni MM, Meng XM, Huang C, Li J. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway. Cancer Lett. 2016;376:10-21. [PMID: 26975630 DOI: 10.1016/j.canlet.2016.03.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
23 Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol 2016; 22(1): 300-325 [PMID: 26755878 DOI: 10.3748/wjg.v22.i1.300] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
24 Guerrieri F, Belloni L, Pediconi N, Levrero M. Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 95-121. [DOI: 10.1007/978-3-319-22330-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Oikawa T, Wauthier E, Dinh TA, Selitsky SR, Reyna-Neyra A, Carpino G, Levine R, Cardinale V, Klimstra D, Gaudio E, Alvaro D, Carrasco N, Sethupathy P, Reid LM. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat Commun 2015;6:8070. [PMID: 26437858 DOI: 10.1038/ncomms9070] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
26 Ju H, Han K, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy: Transgenic mouse models generated by hydrodynamic transfection. Int J Cancer 2016;138:1601-8. [DOI: 10.1002/ijc.29703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
27 Jiang L, Kwong DL, Li Y, Liu M, Yuan YF, Li Y, Fu L, Guan XY. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis 2015;36:1111-20. [PMID: 26246424 DOI: 10.1093/carcin/bgv116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
28 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, Zhang Q, Jiang N. miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein. Med Sci Monit 2015;21:667-73. [PMID: 25731670 DOI: 10.12659/MSM.892515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
30 Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol 2015;62:448-57. [PMID: 25308172 DOI: 10.1016/j.jhep.2014.10.004] [Cited by in Crossref: 391] [Cited by in F6Publishing: 402] [Article Influence: 48.9] [Reference Citation Analysis]
31 Coleman SJ, Grose RP, Kocher HM. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:43-54. [PMID: 27508175 DOI: 10.2147/JHC.S48958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
32 Liu WT, Lu X, Tang GH, Ren JJ, Liao WJ, Ge PL, Huang JF. LncRNAs expression signatures of hepatocellular carcinoma revealed by microarray. World J Gastroenterol 2014; 20(20): 6314-6321 [PMID: 24876753 DOI: 10.3748/wjg.v20.i20.6314] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
33 Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S, Columbano A. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 2014;59:228-41. [PMID: 23857252 DOI: 10.1002/hep.26616] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 10.8] [Reference Citation Analysis]
34 Frau M, Feo CF, Feo F, Pascale RM. New insights on the role of epigenetic alterations in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:65-83. [PMID: 27508177 DOI: 10.2147/JHC.S44506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet. 2014;46:24-32. [PMID: 24316982 DOI: 10.1038/ng.2847] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 8.7] [Reference Citation Analysis]
36 Guerrieri F, Piconese S, Lacoste C, Schinzari V, Testoni B, Valogne Y, Gerbal-Chaloin S, Samuel D, Bréchot C, Faivre J, Levrero M. The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell Death Dis 2013;4:e807. [PMID: 24052075 DOI: 10.1038/cddis.2013.302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
37 Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014;35:9-20. [PMID: 24006223 DOI: 10.1007/s13277-013-1141-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
38 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis 2013;17:375-97. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
39 Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol 2013;25:639-51. [PMID: 23628963 DOI: 10.1097/MEG.0b013e32835e33bb] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
40 Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL, Chen J. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2013;12:171-9. [PMID: 23558072 DOI: 10.1016/s1499-3872(13)60028-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
41 Ju HL, Ahn SH, Kim DY, Baek S, Chung SI, Seong J, Han KH, Ro SW. Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. PLoS One 2013;8:e59869. [PMID: 23555816 DOI: 10.1371/journal.pone.0059869] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
42 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 0.7] [Reference Citation Analysis]
43 Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013;57:840-7. [PMID: 23081718 DOI: 10.1002/hep.26095] [Cited by in Crossref: 259] [Cited by in F6Publishing: 275] [Article Influence: 25.9] [Reference Citation Analysis]
44 Lee NP. The Blood-Biliary Barrier, Tight Junctions and Human Liver Diseases. Advances in Experimental Medicine and Biology 2013. [DOI: 10.1007/978-1-4614-4711-5_8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 Marchetti A, Cicchini C, Santangelo L, Cozzolino AM, Costa V, Tripodi M, Amicone L. Signaling Networks Controlling HCC Onset and Progression: Influence of Microenvironment and Implications for Cancer Gene Therapy. JCT 2013;04:353-358. [DOI: 10.4236/jct.2013.42a042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Zheng L, Liang P, Li J, Huang XB, Liu SC, Zhao HZ, Han KQ, Wang Z. ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth. PLoS One 2012;7:e45412. [PMID: 23049798 DOI: 10.1371/journal.pone.0045412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
47 Li Q, Gao Y, Jia Z, Mishra L, Guo K, Li Z, Le X, Wei D, Huang S, Xie K. Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 2012;143:799-810.e2. [PMID: 22677193 DOI: 10.1053/j.gastro.2012.05.043] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
48 Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117-1121. [PMID: 22922871 DOI: 10.1038/ng.2391] [Cited by in Crossref: 293] [Cited by in F6Publishing: 319] [Article Influence: 26.6] [Reference Citation Analysis]
49 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
50 Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol. 2012;2:467-473. [PMID: 22722078 DOI: 10.1016/j.coviro.2012.05.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
51 Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, Yu MW, Chen CJ, Santella RM. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012;55:1799-808. [PMID: 22234943 DOI: 10.1002/hep.25569] [Cited by in Crossref: 147] [Cited by in F6Publishing: 153] [Article Influence: 13.4] [Reference Citation Analysis]
52 Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012;31:4517-4526. [PMID: 22249248 DOI: 10.1038/onc.2011.631] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
53 Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2011;5:539-552. [PMID: 21780900 DOI: 10.1586/egh.11.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
54 Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, Shang JL, Gao CF, Zhang FR, Wang F, Sun SH. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011;54:1679-89. [PMID: 21769904 DOI: 10.1002/hep.24563] [Cited by in Crossref: 481] [Cited by in F6Publishing: 523] [Article Influence: 40.1] [Reference Citation Analysis]
55 Chang C, Lin S, Su W, Ho C, Jou Y. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene 2012;31:2640-52. [DOI: 10.1038/onc.2011.440] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
56 Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P. Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011;5:410-25. [PMID: 21849266 DOI: 10.1016/j.molonc.2011.07.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
57 Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, Ghiso E, Giordano S, Columbano A. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011;53:2086-96. [PMID: 21391223 DOI: 10.1002/hep.24289] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
58 Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology 2011;53:1932-42. [PMID: 21391225 DOI: 10.1002/hep.24291] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
59 Li W, Li Y, Xu M, Lu Y, Yu H. Role of microRNA in development and progression of glioblastoma. Academic Journal of Second Military Medical University 2011;31:202-205. [DOI: 10.3724/sp.j.1008.2011.00202] [Reference Citation Analysis]
60 Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, Pannell L, Fisher PB, Sarkar D. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology 2011;53:1538-48. [PMID: 21520169 DOI: 10.1002/hep.24216] [Cited by in Crossref: 122] [Cited by in F6Publishing: 129] [Article Influence: 10.2] [Reference Citation Analysis]
61 Alonzi DS, Su YH, Butters TD. Urinary glycan markers for disease. Biochem Soc Trans 2011;39:393-8. [PMID: 21265811 DOI: 10.1042/BST0390393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
62 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int. 2011;2011:403929. [PMID: 21559202 DOI: 10.4061/2011/403929] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
63 Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011;53:854-64. [PMID: 21319186 DOI: 10.1002/hep.24099] [Cited by in Crossref: 90] [Cited by in F6Publishing: 91] [Article Influence: 7.5] [Reference Citation Analysis]
64 Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 2011;71:2718-2727. [PMID: 21324921 DOI: 10.1158/0008-5472.can-10-2705] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
65 Laloo B, Maurel M, Jalvy-delvaille S, Sagliocco F, Grosset C. Analysis of post-transcriptional regulation using the FunREG method. Biochemical Society Transactions 2010;38:1608-14. [DOI: 10.1042/bst0381608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]